论文部分内容阅读
对42名老年常见血栓性疾病非急性梗塞期患者随机给予噻氯匹啶(ticlopidine,TP)125～250 mg/日或阿斯匹林(aspirin,ASA)162.5mg/日,疗程36～39日。服药前后分别测定三项血小板(platelct,Pt)聚集指标,TP组尚同步作血液流变学及血液粘弹性测定。结果发现:对于二磷酸腺苷(ADP)诱导的Pt聚集,TP有极显著的抑制作用(P<0.01),且TP之抑制作用超过ASA(P<0.05)。TP能明显延长出血时间(BT)(P<0.05)、对多项血液流变学及血液粘弹性指标无影响、也无明显副作用。作者认为TP防治血栓性疾病可能是通过降低Pt聚集率和延长BT而起作用的。
Forty-two patients with non-acute infarction of common thrombotic diseases were randomized to receive either 125-250 mg ticlopidine (TP) or 162.5 mg / day aspirin (ASA) for 36-39 days . Before and after taking the drug were measured three platelet (platelct, Pt) aggregation index, TP group is synchronized for hemorheology and blood viscoelastic determination. The results showed that there was a significant inhibitory effect of TP on ADP-induced Pt accumulation (P <0.01), and the inhibitory effect of TP over ASA (P <0.05). TP significantly prolonged the bleeding time (BT) (P <0.05), had no effect on a number of hemorheology and blood viscoelastic indexes, and had no obvious side effects. The authors believe that the prevention and treatment of thrombotic diseases by TP may play a role in reducing the Pt aggregation rate and prolonging BT.